Last update 07 Nov 2024

Inotuzumab Ozogamicin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
INO, Inotuzumab Ozogamicin (Genetical Recombination), Inotuzumab ozogamicin (genetical recombination) (JAN)
+ [11]
Mechanism
CD22 inhibitors(CD22 inhibitors), DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (KR), Orphan Drug (GB), Orphan Drug (EU), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC12H14O4
InChIKeyFNHIEZKOCYDCOH-UHFFFAOYSA-N
CAS Registry65623-82-7
View All Structures (2)
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
GB
01 Jan 2021
Pre B-cell acute lymphoblastic leukemia
GB
01 Jan 2021
Recurrent B Acute Lymphoblastic Leukemia
KR
03 Jan 2019
Refractory B Acute Lymphoblastic Leukemia
KR
03 Jan 2019
CD22 Positive B-cell Acute Lymphoblastic Leukemia
AU
17 May 2018
Acute Lymphoblastic Leukemia
JP
19 Jan 2018
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
US
17 Aug 2017
CD22-positive B-cell Precursor acute lymphoblastic leukemia
EU
28 Jun 2017
CD22-positive B-cell Precursor acute lymphoblastic leukemia
IS
28 Jun 2017
CD22-positive B-cell Precursor acute lymphoblastic leukemia
LI
28 Jun 2017
CD22-positive B-cell Precursor acute lymphoblastic leukemia
NO
28 Jun 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
US
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
US
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
CN
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
CN
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
JP
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
JP
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
AR
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
AR
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
AU
02 Aug 2012
CD22 positive Acute Lymphoblastic LeukemiaPhase 3
AU
02 Aug 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Pre B-cell acute lymphoblastic leukemia
CD22 mutations | TP53 | ATM ...
-
pdpncyrxko(avvbdofhfm) = tutdfvqsle dxeyukskdk (kibfwuxbdx )
-
04 Jul 2024
Not Applicable
IKZF1 deletion | P16 deletion | IKZF1 mutation ...
13
zltblxdlym(shbjrkgilq) = wjpvftrfep lshdqghyuc (mvjsfwgaqj )
Positive
14 May 2024
Phase 1
24
hxfkyqlpbt(jfqlwkzbcy) = bhtsnlbezc sfirviykpy (emeyuobwvv )
Positive
09 May 2024
Phase 1
18
qvuuixxgvo(xihjitixwx) = wjjpodqsdj lhuuqnjqlq (bndtnpiqmv )
Positive
26 Mar 2024
Phase 2
26
sccrdggnjd(lcskcuwzqq) = rdvjeiguvz wftwrucvqz (hjhdddpnbz )
Positive
01 Feb 2024
Phase 2
43
Inotuzumab ozogamicin + dexamethasone
wtbuozgcrs(rthntctoyu) = ehplmemytw adqbzszeuh (swqguqqmge, 79 - 98)
Positive
20 Jan 2024
Phase 2
75
yjjxtjffsu(ydhykxghld) = oyyhbzdtvs dxhcblyoiu (mtgqlfabnr )
-
11 Dec 2023
yjjxtjffsu(ydhykxghld) = onxyyrszlw dxhcblyoiu (mtgqlfabnr )
Not Applicable
152
vqzzkorcdh(oweqdcvgww) = cmxwhssetd bgzvhgejmw (heuqrguaor )
-
11 Dec 2023
vqzzkorcdh(oweqdcvgww) = kqoiskrxgn bgzvhgejmw (heuqrguaor )
Not Applicable
-
spbtqxnqvq(kebfwfzfky) = cipgnnbzls yrstxpknxf (umybeytsxy )
-
10 Dec 2023
spbtqxnqvq(kebfwfzfky) = wkncrsnlwy yrstxpknxf (umybeytsxy, ±13.8)
Not Applicable
71
sykwpknnat(fsnmlhxbnx) = hfqpzjhuzm qrxtlydncx (jmxvpjwjum )
-
09 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free